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The presence of the hepatitis B e antigen 
(HBeAg) in peripheral blood of chronic hepatitis 
B patients is a widely accepted marker of active 
replication of the hepatitis B virus. HBeAg deter- 
mination during interferon therapy is a useful 
guide for t h e  therapeutic regimen. 
The aim of the study was to compare the suit- 
ability of an HBeAg radioimmunoassay (RIA, 
Abbott Laboratories, North Chicago, IL, USA), 
the IMx-HBeAg assay (IMx, Abbott Laboratories) 
and the HBeAg/anti-HBe Amerlite assay (Amer- 
lite, Johnson & Johnson Clinical Diagnostics, 
Cardiff, UK) for semiquantitative monitoring of 
HBeAg during therapy. HBeAg levels in serum 
samples obtained before and during interferon 
therapy were measured using an in-house stan- 
dard calibrated against the Paul Ehrlich Institute 
H BeAg reference preparation (PE I standard). 
When serial dilutions of pretreatment serum 
samples were assayed by the three methods, ra- 
dioimmunoassay was found to be highly sensi- 
tive although it had a very limited working range 
(0.5 to 12 PEI U/ml). A broader linear working 
range was observed for Amerlite (0.5 to 50 PEI 
U/rnl) and the IMx assay (0.5 to 100 PEI U/ml). 
The intra-assay and interassay variations did not 
differ significantly. Since the IMx assay was less 
susceptible to sample variation and had a broad 
working range, semiquantitative measurement 
of HBeAg in one diluted and one undiluted sam- 
ple by this assay may justifiably be introduced as 
routine procedure. Routine semiquantitative 
HBeAg measurement may improve individual 
dose adjustments and t h u s  the success of inter- 
feron therapy. o 1995 Wiley-Liss, Inc. 
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[Main and Thomas, 1990; De Man et al., 19911. The aim 
of any antiviral therapy is to suppress viral replication, 
leading eventually to eradication of the virus. Therapy 
is monitored frequently by measuring hepatitis B virus 
DNA (HBV-DNA) by various hybridization methods. 
The DNA methods are expensive and usually require 
radioisotope facilities. Therefore, the measurement of 
an HBV-(antigen) marker by means of an ELISA-type 
method would be more convenient [Perrillo et al., 
19931. Hepatitis B e antigen (HBeAg), which is a 
marker of active viral replication, is used to monitor 
antiviral therapy. HBeAg seroconversion to anti-HBe 
is generally considered as an indicator of transition to a 
state of viral latency accompanied by normalisation of 
aminotransferase levels [Perrillo, 19881. HBeAg sero- 
conversion reduces the risk of developing cirrhosis and 
decompensated liver disease [Fattovich et al., 19861. 
In view of the serious side effects and the high costs of 
treatment, clinicians tend to prescribe antiviral ther- 
apy for a minimum period. In earlier studies on inter- 
feron treatment of chronic hepatitis B radioimmunoas- 
say was used for semiquantitative determination of 
HBeAg [Schalm et al., 19861. The data from this assay 
were of value in avoiding discontinuation of therapy 
just before HBeAg seroconversion [Janssen et al. , 
19921. 
Recently, two new HBeAg assays which can also be 
adapted to quantify HBeAg have been introduced the 
IMx system (Abbott Laboratories, North Chicago, IL, 
USA) and the Amerlite-HBeAg/anti-HBe (Johnson & 
Johnson, Clinical Diagnostics, Cardiff, UK). The aim of 
the present study was to compare the suitability of RIA, 
IMx/ and the Amerlite methods for semiquantita- 
tive measurement of HBeAg levels during interferon 
therapy. 
MATERIALS AND METHODS 
Assay Systems 
The Abbott (rDNA) HBe RIA is a sandwich radioim- 
munoassay in which beads are coated with human poly- 
INTRODUCTION 
Several antiviral drugs and therapeutic regimens for 
treatment of chronic hepatitis B have been studied 
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clonal anti-HBe. HBeAg from serum binds to this anti- 
HBe which is detected by a second incubation with 
human polyclonal lZ5I-anti-HBe. 
The Abbott HBeAg-IMx assay is based on microparti- 
cle enzyme immunoassay technology [Robbins et al., 
19921. Microparticles coated with human polyclonal 
anti-HBe are added to a serum sample. HBeAg from 
serum binds to the particles coated with anti-HBe. A 
monoclonal anti-HBe alkaline phosphatase conjugate 
is used for detection. The substrate generates a fluores- 
cent signal. 
The Kodak Amerlite immunoassay can detect either 
HBeAg or anti-HBe in a single well. In one incubation 
step the test sample is mixed with horseradish peroxi- 
dase (HRP)-labelled mouse monoclonal anti-HBe com- 
plexed with rDNA-HBeAg in microtitre wells coated 
with a second mouse monoclonal anti-HBe. The two 
HBe-monoclonal antibodies differ in epitope specificity. 
If the patient’s sample contains neither HBeAg nor 
anti-HBe, a limited signal is produced by binding of the 
rDNA-HBeAg-anti-HBe-HRP complex to the solid 
phase. In the presence of any HBeAg in the sample, this 
signal is increased, and in the presence of any anti-HBe 
the signal is reduced. The substrate generates a lumi- 
nescent signal. 
All assays were carried out according to the manufac- 
turers’ recommendations. Results were expressed as a 
sample to negative control signal (S/N). 
Standardization 
To express the amount of HBeAg in standard units 
independent of the assays, a reference preparation ob- 
tained from the Paul Ehrlich Institute (Langen, Ger- 
many) was used. This preparation is defined as contain- 
ing 100 Ulml of antigen. The preparation (PEI 
standard) was diluted in fetal calf serum (FCS), as rec- 
ommended by the manufacturer, and titrated using the 
three assays in parallel with a single HBeAg-positive 
serum sample serving as internal reference (IR). Since 
the PEI standard is only available in limited amounts, 
the IR was used throughout this study. Patient samples 
were diluted with FCS when necessary. 
Serum Samples 
For comparison of quantitative HBeAg measure- 
ments obtained with the three assays, pretreatment 
serum samples from 23 chronic hepatitis B patients 
were used. For evaluation of HBeAg in six alpha-inter- 
feron treated patients, serum samples before the start 
of therapy, during therapy and after therapy were as- 
sayed. Patients were treated for 16 weeks with inter- 
feron (Intron-A, 10 MU three times a week, Scheringl 
Plough, NJ). All patients were tested for antibodies 
against human immunodeficiency virus, cytomegalovi- 
rus, Epstein Barr virus, hepatitis delta virus, and hep- 
atitis C virus. No evidence of concomitant viral infec- 
tions was found. 
RESULTS 
Reference Preparations 
A dilution series of the PEI standard reference prep- 
aration in FCS within the range of the three tests was 
chosen and assayed in the same run as a twofold dilu- 
tion series of the JR (Fig. 1). The dilution curves for the 
PEI standard and the IR were obtained with the RIA 
and the IMx run in parallel. In the Amerlite assay, 
dilution characteristics of the PEI standard and IR 
sample diverged. In comparison to RIA and IMx, ten- 
fold concentrations of the PEI standard and IR had to be 
used to  obtain signals within the range of the Amerlite 
assay. Due to the choice of fetal calf serum, even exten- 
sively diluted samples showed a limited signal above 
the cut-off level in the Amerlite assay. Fetal calf serum 
was nevertheless used throughout the study to avoid 
the need for large quantities of human serum diluent. 
Furthermore, HBeAg seroconversion was established 
in undiluted samples to utilize the highest sensitivity of 
the assay. 
Intra-Assay and Interassay Variation 
For assessment of the reproducibility of each assay 
the IR was assayed six times within the same run and 
once in six different runs of each assay. There were no 
significant differences between the three assays. The 
intra-assay and interassay reproducibilities ranged 
from 2% to 16% (Table I). 
Dynamic Range 
Four serum samples with high levels of HBeAg were 
diluted in 4-fold, &fold or 10-fold steps and assayed by 
Amerlite, RIA and IMx, respectively (Fig. 2). For each 
assay the extent of the individual dilution step was 
obtained from pilot experiments which were intended 
to determine the minimal number of dilutions needed 
to select a fixed dilution for longitudinal observations 
during interferon therapy. From these curves the ac- 
tual working range can be deduced. It was found that 
the lower and upper limits of the HBeAg level which 
can be detected were between 0.5 and 12 PEI U/ml for 
RIA, 0.5 and 100 PEI Uiml for IMx and 0.5 and 50 PEI 
U/ml for Amerlite. 
In both the RIA and the Amerlite assay, increasing 
amounts of HBeAg gave rise to a prozone effect in some 
cases. The Amerlite assay had the greatest variation in 
patient-specific dilution characteristics. 
Standardized Serum HBeAg Levels 
In an attempt to standardize test results, pretreat- 
ment samples from 23 HBeAg-positive and HBV-DNA- 
positive patients and 22 samples obtained from six pa- 
tients during therapy were assayed by each method. 
Within each run the IR panel was also assayed. A refer- 
ence curve was constructed using the test results for the 
I R  by means of linear regression analysis and after 
correction for the dilution factor, the HBeAg level was 
expressed as PEI U/ml for each undiluted sample. Re- 
sults varied from 23 to 3,609 PEI U/ml (median 1,080 
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Fig. 1. A-C: Dilution characteristics of the Paul Ehrlich Institute 
(PEI) preparation for HBeAg (circles) and the Internal Reference (IR) 
panel consisting of four samples (asterisks). The initial amounts of 
PEI standard HBeAg are given in PEI unitdm1 (PEI U/ml). In the 
Amerlite assay a tenfold higher initial level of HBeAg compared to 
RIA and IMx was needed to reach the upper part of the signal range of 
this assay. 
PEI U/ml) for the RIA, 34-7,425 PEI U/ml (median 
1,443 PEI U/ml) for the IMx, and 2.0-2,485 PEI U/ml 
(median 302 PEI U/ml) for the Amerlite. The results of 
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Fig. 2. A-C: Dilution characteristics of four representative pre- 
treatment serum samples from chronic hepatitis B patients deter- 
mined for the IMx, Amerlite and RIA. The 10-fold, 4-fold and 5-fold 
dilution series were tested with IMx, Amerlite and RIA, respectively. 
Dilution factors were chosen to cover the linear part of these curves 
with a minimal number of dilution steps. Dilution series started with 
the undiluted sample in all cases. For each patient identical symbols 
were used in A, B, and C. 
IMx and Amerlite are compared with the results of RIA 
in Figure 3. Compared to  RIA, higher levels of HBeAg 
were observed with the IMx assay and lower levels with 
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Fig. 3. A, B Relationship between HBeAg levels determined with 
the IMx and Amerlite assay and the RIA using the IR after calibration 
with the PEI standard. For the Amerlite assay the unit of HBeAg was 
fixed at the level of 10 PEI U/ml on the PEI standard curve. 
the Amerlite. Spearman’s coefficient for correlation of 
HBeAg levels between the radioimmunoassay and IMx 
and between the radioimmunoassay and Amerlite was 
0.84 and 0.82, respectively. The correlation coefficient 
for IMx versus Amerlite was 0.68. 
Monitoring HBeAg Levels During 
Antiviral Therapy 
A pretreatment serum sample was titrated for each 
patient using the dilution series determined for each 
assay to find the dilution factor which would produce a 
signal in the upper part of the working range of the 
assay under study. This fixed dilution was applied to a 
series of serum samples from that patient. Figure 4 
shows representative results for three patients during a 
16-week course of interferon. When the antigen level 
was no longer detectable in the standard dilution, undi- 
luted serum samples were analysed. 
DISCUSSION 
Clinicians who administer antiviral therapy need a 
reliable, reproducible and easily applicable quantita- 
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Fig. 4. A-C: HBeAg levels in serum samples from two responding 
and one nonresponding patient before, during and after interferon 
therapy. All samples from one patient were run simultaneously. Sym- 
bols: RIA, circles; IMx, crosses; Amerlite, XIS. 
tive assay for HBeAg to monitor HBeAg levels. The 
three HBeAg assays described above could be adapted 
for use as semiquantitative assays. Standardization of 
test results was one of the objectives of this study. The 
PEI standard preparation and an internal standard 
that was calibrated in PEI units by comparison of the 
signal with that of the PEI standard were noted. 
Dilution characteristics of all samples tested were 
very similar by the IMx. Nonparallel dilution curves 
were found for RIA and the Amerlite assay. An increase 
in signal upon dilution of serum samples with high 
initial HBeAg levels was common for both RIA and 
Amerlite but is not easily explained. 
Several investigators have described heterogeneity 
of HBeAg in patient serum [Baba et al., 1986; Matsuda 
and Ohori, 19881. HBeAg epitopes may be presented by 
three different proteins with molecular weights rang- 
ing from 16 kD to 20 kD [Campillo et al., 19921. Fur- 
thermore, these proteins may be aggregated or be im- 
munocomplexed. 
For the three HBeAg assays, anti-HBe antibody sets 
of different origins (mouse monoclonal, human poly- 
clonal) were used for the adherence of HBeAg to the 
solid phase and the conjugate. The Amerlite assay may 
be more susceptible to structural variations of HBeAg 
than the other assays because two different monoclonal 
antibodies with very specific epitopes are used. In addi- 
tion, in Amerlite rDNA-HBeAg is added as assay re- 
agent to allow the detection of anti-HBe in postserocon- 
version samples. 
Therefore, the standard that must as yet be defined 
for standardization should be based on several sources 
of HBeAg to diminish at  least to some degree sample 
(patient)-specific characteristics. This study showed 
that there is a wide range of HBeAg levels in sera. For 
longitudinal observations during therapy using all 
three assays, an extended initial dilution series is re- 
quired to determine a signal in the upper part of the 
working range of the relevant assay. The dynamic 
range of the assay determines the number of dilution 
steps which covers the whole range of possible HBeAg 
levels in unknown patient samples. The smallest num- 
ber of dilution steps was found for IMx followed by 
Amerlite and RIA. Simultaneous assessment of an un- 
diluted specimen and a 11200 dilution by the IMx assay 
may cover the widest range, i.e., from 0.5 to about 
20,000 PEI Uiml. 
The intra-assay variation for all three assays was 
less than 6.5%. The interassay variation ranged from 
5% to  16%. For all three assays the results are satisfac- 
tory for longitudinal studies without repeating previ- 
ous samples under the condition of strict adherence to 
the range of the assay. 
Finally, it should be noted that these HBeAg assays 
were not designed initially for (semi)quantification. 
Quantification panels for Amerlite and IMx are still 
under development. Nevertheless, to help estimate vi- 
ral activity during interferon therapy in a routine set- 
ting these HBeAg assays were adapted and compared. 
It is concluded that the two assays, IMx and Amerlite, 
are more suitable for semiquantitative measurement 
during therapy than the RIA since both assays have a 
wider dynamic range under conditions of comparable 
reproducibility. The IMx assay was found to be less 
susceptible to sample-specific characteristics which 
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